A therapeutic approach has been developed to block EGFR receptor activities by targeted drugs specifically: the use of monoclonal antibodies (mAbs) including cetuximab, or receptor tyrosine kinase inhibitors such as erlotinib in EGFR targeting for the treatment of carcinoma cell subtypes of head and neck, colorectal, pancreatic, and lung cancers has been clinically validated [10, 11, 12, 13]. Here, EGFR is linked to lung carcinoma.